OR WAIT null SECS
Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.
Last month’s cancelled American Academy of Allergy, Asthma & Immunology (AAAAI) 2020 Annual Meeting planned discussion around a series of clinical developments for tezepelumab, the investigational TSLP inhibitor from AstraZeneca and Amgen.
The biologic, which was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) for patients with treated, severe asthma based on phase 2B PATHWAY findings in 2018, had been recently assessed for continued care in patients with severe asthma, as well as those with cat allergies. Such trials, including phase 3 results from PATHWAY, were planned for presentation at AAAAI 2020.
While presentation of those findings is delayed for journal publication, there is plenty to discuss about the potential future benefit and overall use of the biologic agent. In an HCPLive® DocTalk interview, investigator Jonathan Corren, MD, FAAAAI, a Los Angeles-based allergist, discussed the characteristics of tezepelumab relevant to its competing biologics, and what current findings show its benefit for atopic disease to be.
Corren also highlighted the most recent significant findings for tezepelumab, and what still needs to be researched.
“Because the drug may have very profound effects in modifying the type 2 inflammatory response, we’ll have to examine the possibility that you can give it for shorter periods of time,” Corren explained. “But that’s not well established.”